Advertisement
Screener

RAFAEL HOLDINGS, INC. (RFL) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

RAFAEL HOLDINGS, INC. Financing Cash Flow

RAFAEL HOLDINGS, INC. (RFL) reported Financing Cash Flow of -$90.00 thousand for the 9-month period ending 2026-04-30, per its 10-Q filed 2026-06-11.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-06-11

  • RAFAEL HOLDINGS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-04-30 was -$28.00K, a 354.55% decline year-over-year.
  • RAFAEL HOLDINGS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-01-31 was -$32.00K.
  • RAFAEL HOLDINGS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-10-31 was -$30.00K.
  • RAFAEL HOLDINGS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-07-31 was $24.89M.
  • RAFAEL HOLDINGS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $24.83M.
  • RAFAEL HOLDINGS, INC. net cash provided by (used in) financing activities for fiscal 2024 was -$179.00K.
  • RAFAEL HOLDINGS, INC. net cash provided by (used in) financing activities for fiscal 2023 was -$15.22M, a 114.65% decline from fiscal 2022.
  • RAFAEL HOLDINGS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $103.86M, a 242.81% increase from fiscal 2021.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 12 month
2026-04-30-$28.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-11
-$60.00K
derived: sum of 2 quarters · filed 2026-06-11
-$90.00K
10-Q · filed 2026-06-11
$24.80M
derived: sum of 4 quarters · filed 2026-06-11
2026-01-31-$32.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-16
-$62.00K
10-Q · filed 2026-03-16
$24.83M
derived: sum of 3 quarters · filed 2026-03-16
$24.84M
derived: sum of 4 quarters · filed 2026-06-11
2025-10-31-$30.00K
10-Q · filed 2025-12-12
$24.86M
derived: sum of 2 quarters · filed 2025-12-12
$24.88M
derived: sum of 3 quarters · filed 2026-06-11
$24.85M
derived: sum of 4 quarters · filed 2026-06-11
2025-07-31$24.89M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29
$24.91M
derived: sum of 2 quarters · filed 2026-06-11
$24.88M
derived: sum of 3 quarters · filed 2026-06-11
$24.83M
10-K · filed 2025-10-29
2025-04-30$11.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-11
-$16.00K
derived: sum of 2 quarters · filed 2026-06-11
-$64.00K
10-Q · filed 2026-06-11
-$88.00K
derived: sum of 4 quarters · filed 2026-06-11
2025-01-31-$27.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-16
-$75.00K
10-Q · filed 2026-03-16
-$99.00K
derived: sum of 3 quarters · filed 2026-03-16
-$129.00K
derived: sum of 4 quarters · filed 2026-03-16
2024-10-31-$48.00K
10-Q · filed 2025-12-12
-$72.00K
derived: sum of 2 quarters · filed 2025-12-12
-$102.00K
derived: sum of 3 quarters · filed 2025-12-12
-$1.03M
derived: sum of 4 quarters · filed 2025-12-12
2024-07-31-$24.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29
-$54.00K
derived: sum of 2 quarters · filed 2025-10-29
-$986.00K
derived: sum of 3 quarters · filed 2025-10-29
-$179.00K
10-K · filed 2025-10-29
2024-04-30-$30.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-11
-$962.00K
derived: sum of 2 quarters · filed 2025-06-11
-$155.00K
10-Q · filed 2025-06-11
-$190.00K
derived: sum of 4 quarters · filed 2025-06-11
2024-01-31-$932.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-14
-$125.00K
10-Q · filed 2025-03-14
-$160.00K
derived: sum of 3 quarters · filed 2025-03-14
-$186.00K
derived: sum of 4 quarters · filed 2025-03-14
2023-10-31$807.00K
10-Q · filed 2024-12-11
$772.00K
derived: sum of 2 quarters · filed 2024-12-20
$746.00K
derived: sum of 3 quarters · filed 2024-12-20
$595.00K
derived: sum of 4 quarters · filed 2024-12-20
2023-07-31-$35.00K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20
-$61.00K
derived: sum of 2 quarters · filed 2024-12-20
-$212.00K
derived: sum of 3 quarters · filed 2024-12-20
-$15.22M
10-K/A · filed 2024-12-20
2023-04-30-$26.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-14
-$177.00K
derived: sum of 2 quarters · filed 2024-06-14
-$15.18M
10-Q · filed 2024-06-14
-$9.19M
derived: sum of 4 quarters · filed 2024-06-14
2023-01-31-$151.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-03-14
-$15.16M
10-Q · filed 2024-03-14
-$9.16M
derived: sum of 3 quarters · filed 2024-03-14
-$9.16M
derived: sum of 4 quarters · filed 2024-03-14
2022-10-31-$15.01M
10-Q · filed 2023-12-14
-$9.01M
derived: sum of 2 quarters · filed 2023-12-14
-$9.01M
derived: sum of 3 quarters · filed 2023-12-14
-$9.05M
derived: sum of 4 quarters · filed 2023-12-14
2022-07-31$6.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-30
$6.00M
derived: sum of 2 quarters · filed 2023-10-30
$5.96M
derived: sum of 3 quarters · filed 2023-10-30
$103.86M
10-K · filed 2023-10-30
2022-04-30-$1.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-13
-$42.00K
derived: sum of 2 quarters · filed 2023-06-13
$97.87M
10-Q · filed 2023-06-13
$112.39M
derived: sum of 4 quarters · filed 2023-06-13
2022-01-31-$41.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-14
$97.87M
10-Q · filed 2023-03-14
$112.40M
derived: sum of 3 quarters · filed 2023-03-14
$114.36M
derived: sum of 4 quarters · filed 2023-03-14
2021-10-31$97.91M
10-Q · filed 2022-12-13
$112.44M
derived: sum of 2 quarters · filed 2022-12-13
$114.40M
derived: sum of 3 quarters · filed 2022-12-13
$128.16M
derived: sum of 4 quarters · filed 2022-12-13
2021-07-31$14.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31
$16.49M
derived: sum of 2 quarters · filed 2022-10-31
$30.25M
derived: sum of 3 quarters · filed 2022-10-31
$30.30M
10-K · filed 2022-10-31
2021-04-30$1.96M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-06-14
$15.73M
derived: sum of 2 quarters · filed 2022-06-14
$15.77M
10-Q · filed 2022-06-14
$15.77M
derived: sum of 4 quarters · filed 2022-06-14
2021-01-31$13.77M
derived: 10-Q 6 month − 10-Q/A 3 month · filed 2022-03-17
$13.81M
10-Q · filed 2022-03-17
$13.81M
derived: sum of 3 quarters · filed 2022-03-17
$13.83M
derived: sum of 4 quarters · filed 2022-03-17
2020-10-31$43.00K
10-Q/A · filed 2022-02-28
$43.00K
derived: sum of 2 quarters · filed 2022-02-28
$63.00K
derived: sum of 3 quarters · filed 2022-02-28
2020-07-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-10-18
$20.00K
derived: sum of 2 quarters · filed 2021-10-18
-$96.00K
10-K · filed 2021-10-18
2020-04-30$20.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-06-14
-$96.00K
10-Q · filed 2021-06-14
2020-01-31-$116.00K
10-Q · filed 2021-03-17
2019-07-31$35.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-29
$62.00K
derived: sum of 2 quarters · filed 2020-10-29
$30.77M
derived: sum of 3 quarters · filed 2020-10-29
$30.89M
10-K · filed 2020-10-29
2019-04-30$27.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-06-09
$30.74M
derived: sum of 2 quarters · filed 2020-06-09
$30.85M
10-Q · filed 2020-06-09
2019-01-31$30.71M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-03-05
$30.83M
10-Q · filed 2020-03-05
2018-10-31$118.00K
10-Q · filed 2019-12-09
2018-07-31$1.75M
10-K · filed 2019-10-04
2018-01-31$900.00K
10-Q · filed 2019-03-12
2017-07-31$2.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-10-15
$2.93M
derived: sum of 2 quarters · filed 2018-10-15
$22.26M
10-K · filed 2018-10-15
2017-04-30$441.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-06-11
$19.77M
10-Q · filed 2018-06-11
2017-01-31$19.33M
10-Q · filed 2018-03-12
2016-07-31$265.00K
10-K · filed 2018-10-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aditxt, Inc. (ADTX)United States$0.000B
CDT Equity Inc. (CDT)United States$0.000B-0.01
Protagenic Therapeutics, Inc.\new (PTIX)United States$0.001B
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
Nexentis Technologies Inc. (NXTS)$0.002B
ORAGENICS INC (OGEN)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B